This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety of AT-1001 in Healthy Volunteers

This study has been completed.
Information provided by:
Alba Therapeutics Identifier:
First received: October 9, 2006
Last updated: October 10, 2006
Last verified: October 2006
To demonstrate the safety and tolerance of multiple, oral doses of AT-1001

Condition Intervention Phase
Healthy Drug: AT-1001 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Phase 1, Randomized, Double-Blind, Placebo Controlled, Multi-Dose Study to Determine the Safety, Tolerance and Pharmacokinetics of 3 Dose Levels of AT-1001 in Healthy Volunteers

Further study details as provided by Alba Therapeutics:

Primary Outcome Measures:
  • To demonstrate the safety and tolerance of multiple, oral doses of AT-1001
  • To determine whether quantifiable AT-1001 concentrations are present in plasma following oral drug administration and to characterize the pharmacokinetic behavior of AT-1001

Secondary Outcome Measures:
  • Pharmacokinetic Measures

Estimated Enrollment: 24
Study Start Date: January 2006
Estimated Study Completion Date: February 2006
Detailed Description:

Subjects will complete screening and thereafter be admitted to the clinic prior to treatment. Three (3) cohorts of 8 (3:1 ratio drug to placebo) subjects will receive 250 µg, 1 mg, or 4 mg of AT-1001 or matching placebo three times a day for 10 days. The subjects will be evaluated for safety at screening, prior to administration of treatment, and following dosing of the study drug. Serial blood samples will be collected for pharmacokinetic determinations at baseline and 2 hours post morning dose on Days 1, 2, 5, 6 and 10. Blood pressure, pulse, temperature and monitoring for adverse events will occur prior to the morning dose on all other study days. An end of study visit will occur 7-10 days after last dose.

Subjects will be evaluated at screening (medical history, physical examination, vital signs, clinical laboratory testing, and 12-lead electrocardiograms). A physical exam, vital signs, clinical laboratory testing and an EKG will be conducted pre first dose. Vital signs, clinical laboratory testing and EKGs will be monitored post dose. Adverse event reports will be monitored throughout the study. At the end of the study a physical exam, clinical laboratory testing and an EKG will be performed.


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subject must be in generally good health and free of any clinical disease that may interfere with study evaluations.
  • BMI between 18 and 30.

Exclusion Criteria:

  • Subject has been using chronic medications within 30 days prior to treatment (excluding hormonal contraceptives)
  • Subject has taken any medications within 14 days prior to treatment (excluding hormonal contraceptives, additional exceptions at the discretion of the Sponsor).
  • Subject has consumed significant quantities of alcohol (> 3 fl oz. ETOH) within 2 days of treatment visit.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00386490

United States, Maryland
Baltimore, Maryland, United States, 21225
Sponsors and Collaborators
Alba Therapeutics
Study Chair: Blake Paterson, MD Alba Therapeutics
  More Information Identifier: NCT00386490     History of Changes
Other Study ID Numbers: CLIN1001-003
Study First Received: October 9, 2006
Last Updated: October 10, 2006 processed this record on August 18, 2017